Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide
| العنوان: | Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide |
|---|---|
| المؤلفون: | Frank J. Palella, Qingjiang Hou, Jun Li, Jonathan Mahnken, Kimberly J. Carlson, Marcus Durham, Douglas Ward, Jack Fuhrer, Ellen Tedaldi, Richard Novak, Kate Buchacz |
| المصدر: | Journal of acquired immune deficiency syndromes (1999). 92(1) |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Infectious Diseases, Humans, Pharmacology (medical), Integrase Inhibitors, HIV Infections, Weight Gain |
| الوصف: | The timing and magnitude of antiretroviral therapy-associated weight change attributions are unclear.HIV Outpatient Study participants.We analyzed 2007-2018 records of virally suppressed (VS) persons without integrase inhibitor (INSTI) experience who switched to either INSTI-based or another non-INSTI-based ART, and remained VS. We analyzed BMI changes using linear mixed models, INSTI- and tenofovir alafenamide (TAF) contributions to BMI change by linear mixed models-estimated slopes, and BMI inflection points.Among 736 participants (5316 person-years), 441 (60%) switched to INSTI-based ART; the remainder to non-INSTI-based ART. The mean follow-up was 7.15 years for INSTI recipients and 7.35 years for non-INSTI. Preswitch, INSTI and non-INSTI groups had similar median BMI (26.3 versus 25.9 kg/m 2 , P = 0.41). INSTI regimens included raltegravir (178), elvitegravir (112), and dolutegravir (143). Monthly BMI increases postswitch were greater with INSTI than non-INSTI (0.0525 versus 0.006, P0.001). A BMI inflection point occurred 8 months after switch among INSTI users; slopes were similar regardless of TAF use immediately postswitch. Among INSTI + TAF users, during 8 months postswitch, 87% of BMI slope change was associated with INSTI use, 13% with TAF use; after 8 months, estimated contributions were 27% and 73%, respectively. For non-INSTI+TAF, 84% of BMI gain was TAF-associated consistently postswitch. Persons switching from TDF to TAF had greater BMI increases than others ( P0.001).Among VS persons who switched ART, INSTI and TAF use were independently associated with BMI increases. During 8 months postswitch, BMI changes were greatest and most associated with INSTI use; afterward, gradual BMI gain was largely TAF-associated. |
| تدمد: | 1944-7884 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be2f9a577348f834bdef296be54c187Test https://pubmed.ncbi.nlm.nih.gov/36150045Test |
| رقم الانضمام: | edsair.doi.dedup.....2be2f9a577348f834bdef296be54c187 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....2be2f9a577348f834bdef296be54c187 887 3 unknown 886.700134277344 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2be2f9a577348f834bdef296be54c187&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Frank+J%2E+Palella%22">Frank J. Palella</searchLink><br /><searchLink fieldCode="AR" term="%22Qingjiang+Hou%22">Qingjiang Hou</searchLink><br /><searchLink fieldCode="AR" term="%22Jun+Li%22">Jun Li</searchLink><br /><searchLink fieldCode="AR" term="%22Jonathan+Mahnken%22">Jonathan Mahnken</searchLink><br /><searchLink fieldCode="AR" term="%22Kimberly+J%2E+Carlson%22">Kimberly J. Carlson</searchLink><br /><searchLink fieldCode="AR" term="%22Marcus+Durham%22">Marcus Durham</searchLink><br /><searchLink fieldCode="AR" term="%22Douglas+Ward%22">Douglas Ward</searchLink><br /><searchLink fieldCode="AR" term="%22Jack+Fuhrer%22">Jack Fuhrer</searchLink><br /><searchLink fieldCode="AR" term="%22Ellen+Tedaldi%22">Ellen Tedaldi</searchLink><br /><searchLink fieldCode="AR" term="%22Richard+Novak%22">Richard Novak</searchLink><br /><searchLink fieldCode="AR" term="%22Kate+Buchacz%22">Kate Buchacz</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => <i>Journal of acquired immune deficiency syndromes (1999)</i>. 92(1) ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2022 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Infectious+Diseases%22">Infectious Diseases</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Pharmacology+%28medical%29%22">Pharmacology (medical)</searchLink><br /><searchLink fieldCode="DE" term="%22Integrase+Inhibitors%22">Integrase Inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22HIV+Infections%22">HIV Infections</searchLink><br /><searchLink fieldCode="DE" term="%22Weight+Gain%22">Weight Gain</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The timing and magnitude of antiretroviral therapy-associated weight change attributions are unclear.HIV Outpatient Study participants.We analyzed 2007-2018 records of virally suppressed (VS) persons without integrase inhibitor (INSTI) experience who switched to either INSTI-based or another non-INSTI-based ART, and remained VS. We analyzed BMI changes using linear mixed models, INSTI- and tenofovir alafenamide (TAF) contributions to BMI change by linear mixed models-estimated slopes, and BMI inflection points.Among 736 participants (5316 person-years), 441 (60%) switched to INSTI-based ART; the remainder to non-INSTI-based ART. The mean follow-up was 7.15 years for INSTI recipients and 7.35 years for non-INSTI. Preswitch, INSTI and non-INSTI groups had similar median BMI (26.3 versus 25.9 kg/m 2 , P = 0.41). INSTI regimens included raltegravir (178), elvitegravir (112), and dolutegravir (143). Monthly BMI increases postswitch were greater with INSTI than non-INSTI (0.0525 versus 0.006, P0.001). A BMI inflection point occurred 8 months after switch among INSTI users; slopes were similar regardless of TAF use immediately postswitch. Among INSTI + TAF users, during 8 months postswitch, 87% of BMI slope change was associated with INSTI use, 13% with TAF use; after 8 months, estimated contributions were 27% and 73%, respectively. For non-INSTI+TAF, 84% of BMI gain was TAF-associated consistently postswitch. Persons switching from TDF to TAF had greater BMI increases than others ( P0.001).Among VS persons who switched ART, INSTI and TAF use were independently associated with BMI increases. During 8 months postswitch, BMI changes were greatest and most associated with INSTI use; afterward, gradual BMI gain was largely TAF-associated. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1944-7884 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be2f9a577348f834bdef296be54c187" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2be2f9a577348f834bdef296be54c187</link><br /><link linkTarget="URL" linkTerm="https://pubmed.ncbi.nlm.nih.gov/36150045" linkWindow="_blank">https://pubmed.ncbi.nlm.nih.gov/36150045</link> ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....2be2f9a577348f834bdef296be54c187 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => Undetermined
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Infectious Diseases
[Type] => general
)
[1] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[2] => Array
(
[SubjectFull] => Pharmacology (medical)
[Type] => general
)
[3] => Array
(
[SubjectFull] => Integrase Inhibitors
[Type] => general
)
[4] => Array
(
[SubjectFull] => HIV Infections
[Type] => general
)
[5] => Array
(
[SubjectFull] => Weight Gain
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Weight Gain and Metabolic Effects in Persons With HIV Who Switch to ART Regimens Containing Integrase Inhibitors or Tenofovir Alafenamide
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Frank J. Palella
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Qingjiang Hou
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jun Li
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jonathan Mahnken
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kimberly J. Carlson
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Marcus Durham
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Douglas Ward
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jack Fuhrer
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ellen Tedaldi
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Richard Novak
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kate Buchacz
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 05
[M] => 05
[Type] => published
[Y] => 2022
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 19447884
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsair
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 92
)
[1] => Array
(
[Type] => issue
[Value] => 1
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Journal of acquired immune deficiency syndromes (1999)
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |